US Stock MarketDetailed Quotes
INKT MiNK Therapeutics
- 0.790
- -0.020-2.47%
Close Aug 9 16:00 ET
- 0.830
- +0.040+5.00%
Post 20:02 ET
27.43MMarket Cap-1338P/E (TTM)
0.811High0.785Low47.32KVolume0.811Open0.810Pre Close37.86KTurnover0.89%Turnover RatioLossP/E (Static)34.73MShares1.90052wk High-1.35P/B4.21MFloat Cap0.75052wk Low--Dividend TTM5.33MShs Float22.155Historical High--Div YieldTTM3.15%Amplitude0.750Historical Low0.800Avg Price1Lot Size
MiNK Therapeutics Stock Forum
Sign in to post a comment
$MiNK Therapeutics (INKT.US)$ Mink Therapeutics Regains Compliance With Nasdaq Capital Market Requirement
4
$MiNK Therapeutics (INKT.US)$ NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at ...
MiNK Therapeutics Secures $5.8 Million in Private Placement to Fuel Cancer Therapy Development.
MiNK Therapeutics, Inc. (NASDAQ: INKT), a company in the biopharmaceutical sector, has announced an essential milestone in its quest to revolutionize cancer treatment. With a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, MiNK has...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a company in the biopharmaceutical sector, has announced an essential milestone in its quest to revolutionize cancer treatment. With a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, MiNK has...
$MiNK Therapeutics (INKT.US)$ Benzinga· 2 mins
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK-215 Clinical Trials
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK-215 Clinical Trials
$MiNK Therapeutics (INKT.US)$
NEWS
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
NEWS
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
2
4
$MiNK Therapeutics (INKT.US)$
CEO bought a lot
CEO bought a lot
$MiNK Therapeutics (INKT.US)$ this one quite similar to $Ambrx Biopharma (AMAM.US)$
Gene therapies..hot cake for now and duti
Gene therapies..hot cake for now and duti
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Seraphicall : Not running
means buy
Trytosaveabit OP Seraphicall : I have to go through my notes to be sure. But it may be a decent swing trade. I believe there is to be some catalyst coming. Just can’t remember what/when off top of my mind? Grrr. Hehehe
Seraphicall Trytosaveabit OP : Do share with me when you recall too ya
Seraphicall Trytosaveabit OP : Thanks in advance